SAN FRANCISCO – As California’s year-long drought continued, Regeneron Pharmaceuticals Inc. refreshed investors at the 32nd Annual J.P. Morgan Healthcare Conference (JPM) with news of a new deal for a combination therapy in wet age-related macular degeneration (AMD).